DE3763863D1 - Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel. - Google Patents

Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel.

Info

Publication number
DE3763863D1
DE3763863D1 DE8787102216T DE3763863T DE3763863D1 DE 3763863 D1 DE3763863 D1 DE 3763863D1 DE 8787102216 T DE8787102216 T DE 8787102216T DE 3763863 T DE3763863 T DE 3763863T DE 3763863 D1 DE3763863 D1 DE 3763863D1
Authority
DE
Germany
Prior art keywords
phenyl
alkyl
substituted
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787102216T
Other languages
English (en)
Inventor
Donald E Butler
Walter H Moos
John H Dodd
Haile Tecle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of DE3763863D1 publication Critical patent/DE3763863D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE8787102216T 1986-02-18 1987-02-17 Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel. Expired - Fee Related DE3763863D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/830,035 US4745123A (en) 1986-02-18 1986-02-18 Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents

Publications (1)

Publication Number Publication Date
DE3763863D1 true DE3763863D1 (de) 1990-08-30

Family

ID=25256160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787102216T Expired - Fee Related DE3763863D1 (de) 1986-02-18 1987-02-17 Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel.

Country Status (8)

Country Link
US (1) US4745123A (de)
EP (1) EP0235663B1 (de)
JP (1) JPH0832682B2 (de)
AT (1) ATE54910T1 (de)
CA (1) CA1285939C (de)
DE (1) DE3763863D1 (de)
ES (1) ES2029801T3 (de)
GR (1) GR3000682T3 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
JP2003522767A (ja) * 2000-02-11 2003-07-29 バーテックス ファーマシューティカルズ インコーポレイテッド ニューロン損傷の処置または予防のためのピペラジンおよびピペリジン誘導体
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
TWI280239B (en) * 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
CN101146775B (zh) 2005-03-23 2012-07-18 弗·哈夫曼-拉罗切有限公司 用于呕吐的用作nk-i拮抗剂的代谢物
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
MY143784A (en) 2005-09-23 2011-07-15 Hoffmann La Roche Novel dosage formulation
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
ES2728225T3 (es) 2009-02-20 2019-10-23 2 Bbb Medicines B V Sistema de administración de fármacos a base de glutatión
EP2427178B1 (de) 2009-05-06 2023-01-04 Laboratory Skin Care, Inc. Dermale freisetzungszusammensetzung mit wirkstoff-calciumphosphat-partikelkomplexen und anwendungsverfahren
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4467095A (en) * 1969-02-10 1984-08-21 Fmc Corporation Anticholinergic compounds
GB1392810A (en) * 1971-10-29 1975-04-30 Wyeth John & Brother Ltd Pharmaceutical compositions containing thioamides and nitriles
US4064253A (en) * 1973-10-10 1977-12-20 Teng Hian Khoe Method of suppressing snoring
US4096268A (en) * 1974-11-14 1978-06-20 Bayer Aktiengesellschaft 1-Methyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid esters and a method of use for combating insects or acarids
US4238488A (en) * 1978-11-17 1980-12-09 Imperial Chemical Industries Limited Carboxylic acid derivatives of N-substituted benzyl-1,2,5,6-tetrahydropyridines
US4383999A (en) * 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters

Also Published As

Publication number Publication date
ATE54910T1 (de) 1990-08-15
JPH0832682B2 (ja) 1996-03-29
EP0235663B1 (de) 1990-07-25
CA1285939C (en) 1991-07-09
ES2029801T3 (es) 1992-10-01
GR3000682T3 (en) 1991-09-27
JPS62192358A (ja) 1987-08-22
US4745123A (en) 1988-05-17
EP0235663A1 (de) 1987-09-09

Similar Documents

Publication Publication Date Title
DE3763863D1 (de) Substituierte tetrahydro-3-pyridincarbonsaeuren, ihre ester und amide als cholinergische mittel.
DK0687266T3 (da) Heterocykliske forbindelser og deres fremstilling og anvendelse
TR199801642T2 (xx) Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
CA2449402A1 (en) Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases
DK0453042T3 (da) Hidtil ukendte 2 9-disubstituerede 4H-pyhrido[1 2-a]pyridin-4-oner
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
CA2382654A1 (en) Novel a-500359 derivatives
AU2287197A (en) Heterocyclic compounds and their preparation and use
GEP19970838B (en) Process for obtaining 3-(methyltio, methylsulphinyl or methylsulphonyl)-4-quinolone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee